Trial Profile
A phase III, placebo-controlled study of saroglitazar (Lipaglyn) compared with standard of care for the treatment of lipodystrophy
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 24 Jun 2014
Price :
$35
*
At a glance
- Drugs Saroglitazar (Primary)
- Indications Lipodystrophy
- Focus Adverse reactions; Therapeutic Use
- 24 Jun 2014 New trial record